Mersana Therapeutics Inc (MRSN)

Currency in USD
0.363
+0.024(+7.07%)
Closed·
After Hours
0.372+0.009(+2.479%)
·
MRSN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MRSN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.3390.378
52 wk Range
0.2592.830
Key Statistics
Prev. Close
0.363
Open
0.34
Day's Range
0.339-0.378
52 wk Range
0.259-2.83
Volume
2.86M
Average Vol. (3m)
2.8M
1-Year Change
-83.19%
Book Value / Share
-0.25
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MRSN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.286
Upside
+1,080.64%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Mersana Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Mersana Therapeutics Inc Company Profile

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Mersana Therapeutics Inc Earnings Call Summary for Q1/2025

  • Q1 2025 net loss of $24.1M, EPS -0.19 met expectations; revenue of $2.75M missed $6.05M forecast; stock up 6.14% to $0.38
  • Strategic restructuring and workforce reduction announced to extend cash runway into mid-2026; focus on breast cancer treatment pipeline
  • Cash and equivalents at $102.3M; net cash used in operations $29.3M; company maintains strong liquidity with more cash than debt
  • Initial clinical expansion data expected in H2 2025; potential for randomized Phase 3 trial focusing on progression-free and overall survival
  • Risks include revenue shortfall, clinical trial uncertainties, competitive pressures, and potential impacts of workforce reduction
Last Updated: 05/15/2025, 08:54 AM
Read Full Transcript

Compare MRSN to Peers and Sector

Metrics to compare
MRSN
Peers
Sector
Relationship
P/E Ratio
−0.6x−1.5x−0.5x
PEG Ratio
−0.01−0.020.00
Price / Book
−1.5x1.3x2.6x
Price / LTM Sales
1.3x50.6x3.2x
Upside (Analyst Target)
-227.9%43.8%
Fair Value Upside
Unlock10.0%5.1%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4.286
(+1,080.64% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.19 / -0.19
Revenue / Forecast
2.75M / 6.05M
EPS Revisions
Last 90 days

MRSN Income Statement

People Also Watch

0.442
NXTE
-0.23%
3.285
DOMI
-0.30%
0.1458
APE
+2.24%
3.14
GEST
-0.51%
57.450
ASTS
+9.16%

FAQ

What Is the Mersana Therapeutics (MRSN) Stock Price Today?

The Mersana Therapeutics stock price today is 0.36

What Stock Exchange Does Mersana Therapeutics Trade On?

Mersana Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Mersana Therapeutics?

The stock symbol for Mersana Therapeutics is "MRSN."

What Is the Mersana Therapeutics Market Cap?

As of today, Mersana Therapeutics market cap is 45.28M.

What Is Mersana Therapeutics's Earnings Per Share (TTM)?

The Mersana Therapeutics EPS (TTM) is -0.60.

When Is the Next Mersana Therapeutics Earnings Date?

Mersana Therapeutics will release its next earnings report on Aug 06, 2025.

From a Technical Analysis Perspective, Is MRSN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Mersana Therapeutics Stock Split?

Mersana Therapeutics has split 0 times.

How Many Employees Does Mersana Therapeutics Have?

Mersana Therapeutics has 102 employees.

What is the current trading status of Mersana Therapeutics (MRSN)?

As of Jul 18, 2025, Mersana Therapeutics (MRSN) is trading at a price of 0.36, with a previous close of 0.36. The stock has fluctuated within a day range of 0.34 to 0.38, while its 52-week range spans from 0.26 to 2.83.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.